ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study

Autor: Chavez, Julio C. 1, Michot, Jean-Marie 2, Carpio, Cecilia 3, Ferrari, Silvia 4, Feldman, Tatyana A. 5, Morillo, Daniel 6, Kuruvilla, John 7, Pinto, Antonio 8, Ribrag, Vincent 2, Bachy, Emmanuel 9, Buchholz, Tonia J. 10, Carrancio, Soraya 11, Chou, Wen-Chi 12, Guarinos, Carla 13, Wu, Fan 14, Li, Shaoyi 15, Patah, Poliana 16, Pourdehnad, Michael 17, Nastoupil, Loretta 18
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S377-S378
Databáze: ScienceDirect
Externí odkaz: